Acorah Software Products - Accounts Production 16.6.920 false true true 31 December 2023 1 January 2023 false 1 January 2024 31 December 2024 31 December 2024 13240109 Mr Pasi Ruokostenohja Mr Niko Nevala Miss Sunita Pall 75Pharma Group Limited true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13240109 2023-12-31 13240109 2024-12-31 13240109 2024-01-01 2024-12-31 13240109 frs-core:CurrentFinancialInstruments 2024-12-31 13240109 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-01-01 2024-12-31 13240109 frs-core:OtherResidualIntangibleAssets 2024-12-31 13240109 frs-core:OtherResidualIntangibleAssets 2023-12-31 13240109 frs-core:ShareCapital 2024-12-31 13240109 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 13240109 frs-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13240109 frs-bus:FilletedAccounts 2024-01-01 2024-12-31 13240109 frs-bus:SmallEntities 2024-01-01 2024-12-31 13240109 frs-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 13240109 frs-bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13240109 1 2024-01-01 2024-12-31 13240109 frs-bus:Director1 2024-01-01 2024-12-31 13240109 frs-bus:Director1 2023-12-31 13240109 frs-bus:Director1 2024-12-31 13240109 frs-bus:Director2 2024-01-01 2024-12-31 13240109 frs-bus:Director3 2024-01-01 2024-12-31 13240109 frs-countries:EnglandWales 2024-01-01 2024-12-31 13240109 2022-12-31 13240109 2023-12-31 13240109 2023-01-01 2023-12-31 13240109 frs-core:CurrentFinancialInstruments 2023-12-31 13240109 frs-core:ShareCapital 2023-12-31 13240109 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31
Registered number: 13240109
75Pharma Limited
Unaudited Financial Statements
For The Year Ended 31 December 2024
Accountum Limited
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2—4
Page 1
Balance Sheet
Registered number: 13240109
2024 2023
Notes £ £ £ £
FIXED ASSETS
Intangible Assets 4 85,470 85,470
85,470 85,470
CURRENT ASSETS
Debtors 5 28,256 3,605
Cash at bank and in hand 5,401 5,401
33,657 9,006
Creditors: Amounts Falling Due Within One Year 6 (362,998 ) (179,018 )
NET CURRENT ASSETS (LIABILITIES) (329,341 ) (170,012 )
TOTAL ASSETS LESS CURRENT LIABILITIES (243,871 ) (84,542 )
NET LIABILITIES (243,871 ) (84,542 )
CAPITAL AND RESERVES
Called up share capital 7 1,000 1,000
Profit and Loss Account (244,871 ) (85,542 )
SHAREHOLDERS' FUNDS (243,871) (84,542)
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Pasi Ruokostenohja
Director
03/12/2025
The notes on pages 2 to 4 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
75Pharma Limited is a private company, limited by shares, incorporated in England & Wales, registered number 13240109 . The registered office is 123 Buckingham Palace Road, London, SW1W 9SH.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
The functional currency of the company is considered to be pound sterling (£) because that is the currency of the primary economic environment in which the company operates. The financial statements are presented in pound sterling (£).
Summary of disclosure exemptions
The company meets the definition of a qualifying entity under FRS 102 and has therefore taken advantage of the disclosure exemptions available to it in respect of its separate financial statements. Exemptions have been taken in these separate company financial statements in relation to financial instruments, presentation of a cash flow statement, transactions with group entities and remuneration of key management personnel.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets relate to license authorisations for the ability to sell in the UK. It is estimated by management that this asset has a useful economic life of 20 years and will be amortised to profit and loss account accordingly, from when trade is expected to commence in 2025 (post balance sheet date).
2.4. Financial Instruments
The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.
2.5. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.6. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
2.7. Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Page 2
Page 3
2.8. Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2023: NIL)
- -
4. Intangible Assets
Licences
£
Cost
As at 1 January 2024 85,470
As at 31 December 2024 85,470
Net Book Value
As at 31 December 2024 85,470
As at 1 January 2024 85,470
5. Debtors
2024 2023
£ £
Due within one year
Prepayments and accrued income - 504
Other debtors 28,256 2,101
Amounts owed by group undertakings - 1,000
28,256 3,605
Amounts due from group companies are unsecured, carry no interest and are repayable on demand.
6. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Other creditors 4,539 4,539
Amounts owed to group undertakings 358,459 174,479
362,998 179,018
Amounts due to group companies are unsecured, carry no interest and are repayable on demand.
7. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 1,000 1,000
Page 3
Page 4
8. Directors Advances, Credits and Guarantees
Included within other creditors are the following loans to directors:
As at 1 January 2024 Amounts advanced Amounts repaid Amounts written off As at 31 December 2024
£ £ £ £ £
Mr Pasi Ruokostenohja (3,939 ) - - - (3,939 )
The above loan is unsecured, interest free and repayable on demand.
9. Related Party Transactions
The compant is a wholly owned subsidiary member of its group and has therefore taken advantage of the provisions of Section 33.1A of FRS102 not to disclose transactions with entities that are wholly owned members of the group. There were no other related party transactions to disclose. 
10. Ultimate Controlling Party
The immediate Parent undertaking is 75Pharma Group limited and there is no requirment for consolidated reports. 
Page 4